{"eventGroups":[{"description":"Patients in the placebo group received the same treatment during the same time, but in this case the laser tip produced no light.\n\nPlacebo (DMC, São Paulo, Brazil): The placebo (DMC, São Paulo, Brazil) was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.Patients in the placebo group received the same treatment during the same time, but in this case the laser tip produced no light.","id":"EG000","otherNumAffected":17,"otherNumAtRisk":47,"seriousNumAffected":17,"seriousNumAtRisk":47,"title":"Placebo"},{"description":"The investigators used a diode laser (DMC, São Paulo, Brazil) InGaAlP (indium phosphide, gallium and aluminum), with 100 mW, 4J/cm ², with an area of 0.24 cm ². The laser was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.\n\nLow Level Laser Therapy- (DMC, São Paulo, Brazil): Diode laser (DMC,São Paulo, Brazil) InGaAlP (indium phosphide, gallium and aluminum), with 100 mW, 4J/cm ², with an area of 0.24 cm ². The laser was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.","id":"EG001","otherNumAffected":10,"otherNumAtRisk":47,"seriousNumAffected":15,"seriousNumAtRisk":47,"title":"Low Level Laser Therapy"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Distribution of severe oral pain intensity","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":47,"numEvents":17},{"groupId":"EG001","numAffected":10,"numAtRisk":47,"numEvents":10}],"term":"Gastrointestinal disorders"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Unplanned radiotherapy interruptions due to radiodermatis: Laser group = 7 patients and Placebo group = 4 patients","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":47,"numEvents":4},{"groupId":"EG001","numAffected":7,"numAtRisk":47,"numEvents":7}],"term":"Radiodermatitis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Unplanned radiotherapy interruptions due to pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":47,"numEvents":1},{"groupId":"EG001","numAffected":1,"numAtRisk":47,"numEvents":1}],"term":"Pneumonia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Unplanned chemotherapy interruptions or modification","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":47,"numEvents":5},{"groupId":"EG001","numAffected":3,"numAtRisk":47,"numEvents":3}],"term":"Renal and urinary disorders"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Unplanned chemotherapy interruptions or modification","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":47,"numEvents":3},{"groupId":"EG001","numAffected":4,"numAtRisk":47,"numEvents":4}],"term":"Ear and labyrinth disorders"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Unplanned chemotherapy interruptions or modification","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":47,"numEvents":4},{"groupId":"EG001","numAffected":0,"numAtRisk":47,"numEvents":0}],"term":"Blood and lymphatic system disorders"}],"timeFrame":"3 years"}